# A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

> **NCT03472560** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 61 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Urothelial Cancer

## Interventions

- **DRUG:** Avelumab (MSB0010718C)
- **DRUG:** Axitinib (AG-013736)

## Key facts

- **NCT ID:** NCT03472560
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-02
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-02-09
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472560, "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03472560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*